Role of EPO and TCF7L2 Gene Polymorphism Contribution to the Occurrence of Diabetic Retinopathy

Table 4

Frequences of genotypes and alleles of EPO and TCF7L genes polymorphisms in diabetes retinopathy patients and diabetes mellitus patients.

SNP	Genotype	DR (%)	DM (%)	value	OR (95% CI)
	Allele	()			()
	AA	(71.88%) 230	(63.20%) 79	0.074	1.488 (0.961-2.305)
	AC	(25.62%) 82	(30.40%) 38	0.308	0.789 (0.500-1.245)
rs551238; (EPO1)	CC	(2.50%) 8	(6.40%) 8	0.047	0.375 (0.138-1.022)
	A	(97.50%) 312	(78.4%) 196	0.025	1.524 (1.052-2.206)
	C	(29.13%) 90	(36.80%) 46	0.025	0.656 (0.453-0.950)
	GG	(1.88%) 6	(3.20%) 4	0.397	0.578 (0.160-2.084)
	GT	(26.88%) 86	(29.60%) 37	0.563	0.874 (0.554-1.380)
rs1617640; (EPO 2)	TT	(71.25%) 228	(67.20%) 84	0.402	1.210 (0.775-1.888)
	G	(28.75%) 92	(32.80%) 41	0.326	0.824 (0.559-1.214)
	T	(98.13%) 314	(96.80%) 121	0.326	1.214 (0.824-1.789)
	CC	(87.19%) 279	(96.00%) 120	0.006	0.284 (0.109-0.735)
	CT	(12.81%) 41	(4.00%) 5	0.006	3.527 (1.360-9.145)
rs7903146; (TCF7L2)	TT	(0) 0	(0) 0
	C	(100.00%) 320	(100.00%) 120	0.008	0.298 (0.116-0.763)
	T	(12.81%) 41	(4.00%) 5	0.008	3.354 (1.310-8.588)

OR: odds ratio.